Thai Ministry, U.S. Industries Agree To Compulsory License Compromise
This article was originally published in PharmAsia News
Executive Summary
Thai officials and U.S. industries have agreed in principle to make some drugs more accessible to Thais short of imposing compulsory licenses. Thailand's Commerce Ministry met with groups representing U.S. drug makers and biotech companies. The three parties agreed to cooperate on Thai research and development to give the nation the capability of producing its own less-expensive quality drugs. In exchange, the government would refrain from imposing compulsory licensing except as a last resort. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.